StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/301% above fair value
$27.60−1.16 (-4.03%)

Close on Nov 20, 2026Market cap $1.65BP/E –Yield –

Agios Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Agios Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$365.25M. For fiscal 2025 it was -$377.29M. The highest annual figure on record is $28.65M in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$377.29M–
FY2024Dec 31, 2024-$391.53M–
FY2023Dec 31, 2023-$297.06M–
FY2022Dec 31, 2022-$314.36M–
FY2021Dec 31, 2021-$413.06M–
FY2020Dec 31, 2020-$304.87M–
FY2019Dec 31, 2019-$382.65M–
FY2018Dec 31, 2018-$311.41M–
FY2017Dec 31, 2017-$289.86M-1111.8%
FY2016Dec 31, 2016$28.65M–
FY2015Dec 31, 2015-$97.11M–
FY2014Dec 31, 2014-$61.57M–
FY2013Dec 31, 2013-$57.69M–
FY2012Dec 31, 2012-$51.02M–
FY2011Dec 31, 2011-$17.13M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$58.52M–
Q1 FY2026Mar 31, 2026-$119.69M–
Q4 FY2025Dec 31, 2025-$97.33M–
Q3 FY2025Sep 30, 2025-$89.71M–
Q2 FY2025Jun 30, 2025-$78.00M–
Q1 FY2025Mar 31, 2025-$112.26M–
Q4 FY2024Dec 31, 2024-$134.13M–
Q3 FY2024Sep 30, 2024-$84.64M–
Q2 FY2024Jun 30, 2024-$72.75M–
Q1 FY2024Mar 31, 2024-$100.01M–
Q4 FY2023Dec 31, 2023-$72.72M–
Q3 FY2023Sep 30, 2023-$62.01M–
Q2 FY2023Jun 30, 2023-$66.75M–
Q1 FY2023Mar 31, 2023-$95.58M–
Q4 FY2022Dec 31, 2022-$66.28M–
Q3 FY2022Sep 30, 2022-$71.39M–
Q2 FY2022Jun 30, 2022-$76.16M–
Q1 FY2022Mar 31, 2022-$100.54M–
Q4 FY2021Dec 31, 2021-$88.60M–
Q3 FY2021Sep 30, 2021-$85.16M–
Q2 FY2021Jun 30, 2021-$117.54M–
Q1 FY2021Mar 31, 2021-$121.76M–
Q4 FY2020Dec 31, 2020-$49.96M–
Q3 FY2020Sep 30, 2020-$73.41M–
Q2 FY2020Jun 30, 2020-$71.94M–
Q1 FY2020Mar 31, 2020-$109.55M–
Q4 FY2019Dec 31, 2019-$100.29M–
Q3 FY2019Sep 30, 2019-$87.63M–
Q2 FY2019Jun 30, 2019-$89.42M–
Q1 FY2019Mar 31, 2019-$105.31M–
Q4 FY2018Dec 31, 2018-$75.24M–
Q3 FY2018Sep 30, 2018-$66.98M–
Q2 FY2018Jun 30, 2018-$68.76M–
Q1 FY2018Mar 31, 2018-$100.43M–
Q4 FY2017Dec 31, 2017-$75.73M–
Q3 FY2017Sep 30, 2017-$79.73M–
Q2 FY2017Jun 30, 2017-$60.02M–
Q1 FY2017Mar 31, 2017-$74.37M–
Q4 FY2016Dec 31, 2016-$52.45M–
Q3 FY2016Sep 30, 2016-$52.46M–

More Agios Pharmaceuticals figures

See a number that looks wrong?